Opendata, web and dolomites

ReSpire SIGNED

Respirable Advanced Therapeutics for Cystic Fibrosis & other Lung Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ReSpire" data sheet

The following table provides information about the project.

Coordinator
OMNISPIRANT LIMITED 

Organization address
address: RATHRONAN
city: CLONMEL TIPPERARY
postcode: E91D9N2
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://www.omnispirant.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OMNISPIRANT LIMITED IE (CLONMEL TIPPERARY) coordinator 50˙000.00

Map

 Project objective

Via the SME Instrument OmniSpirant Ltd will mature its stem cell exosome-packaged gene therapy with lung mucus penetration properties which will be more effective (improved lung function, reversal of lung damage and superior CFTR gene expression and function) and also be applicable to 100% of the CF global population. This approach, using a combined patent pending exosome surface engineering for enhanced mucus penetration and cell transfection with a tailored vibrating mesh nebulisation aerosol delivery method will provide a unique, potentially disruptive, therapeutic modality for CF and many other lung diseases with high unmet medical need. Our competitive advantage and Unique Selling Points lower current effectiveness barriers and make the OmniSpirant exosome technology the only therapeutic delivery method that could provide a truly effective treatment for CF, thus improving both survival rates the quality of life of CF suffers. Importantly, the quality of life for CF patients will increase to point where they are able to work. The OmniSpirant system will, over time, be regarded as an essential weapon in the armoury of health systems in the battle against other serious respiratory conditions affecting major patient populations such as lung cancer and COPD, globally. The overall objective of our feasibility study is to demonstrate the potential value of the combined gene therapy system maturation based on a comprehensive analysis of the business concept in terms of technical, commercial and financial viability. The outcome of the study will be a full Business Plan that will feed into a Phase 2 project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESPIRE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESPIRE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More